

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM S-8**  
**REGISTRATION STATEMENT**  
*UNDER*  
*THE SECURITIES ACT OF 1933*

---

**NeuroPace, Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**22-3550230**  
(I.R.S. Employer  
Identification No.)

**455 N. Bernardo Avenue**  
**Mountain View, California 94043**  
**(650) 237-2700**  
(Address of Principal Executive Offices) (Zip Code)

**NeuroPace, Inc. 2021 Equity Incentive Plan**  
**NeuroPace, Inc. 2021 Employee Stock Purchase Plan**  
(Full titles of the plans)

**Michael Favet**  
**President and Chief Executive Officer**  
**NeuroPace, Inc.**  
**455 N. Bernardo Avenue**  
**Mountain View, California 94043**  
**(650) 237-2700**

(Name and address of agent for service) (Telephone number, including area code, of agent for service)

---

*Copies to:*

**Mark B. Weeks**  
**Seth J. Gottlieb**  
**Brett D. White**  
**Cooley LLP**  
**3175 Hanover Street**  
**Palo Alto, California 94304**  
**(650) 843-5000**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer   
Non-accelerated filer

Accelerated filer   
Smaller reporting company   
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

---

## EXPLANATORY NOTE

This Registration Statement on Form S-8 is being filed by NeuroPace, Inc. (the “**Registrant**”) with the Securities and Exchange Commission (the “**Commission**”) for the purpose of registering (i) an additional 1,222,649 shares of the Registrant’s common stock, par value \$0.001 per share (the “**Common Stock**”), to be issued pursuant to the Registrant’s 2021 Equity Incentive Plan (the “**2021 Plan**”) and (ii) an additional 244,529 shares of Common Stock to be issued pursuant to the Registrant’s 2021 Employee Stock Purchase Plan (the “**2021 ESPP**”). The Registrant previously registered shares of its Common Stock for issuance under the 2021 Plan and 2021 ESPP on a Registration Statement on Form S-8 ([File No. 333-255453](#)) filed with the Commission on April 23, 2021 (the “**Prior Form S-8**”).

This Registration Statement relates to securities of the same class as that to which the Prior Form S-8 relates and is submitted in accordance with General Instruction E to Form S-8. Pursuant to General Instruction E of Form S-8, the contents of the Prior Form S-8, to the extent relating to the registration of Common Stock issuable under the 2021 Plan and 2021 ESPP, are incorporated herein by reference and made part of this Registration Statement.

## PART II

### INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

#### Item 3. Incorporation of Documents By Reference.

The following documents filed by NeuroPace, Inc. (the “**Registrant**”) with the Commission are incorporated by reference into this Registration Statement:

(a) the Registrant’s Annual Report on [Form 10-K](#) for the fiscal year ended December 31, 2021, filed with the Commission on March 10, 2022 (File No. 001-40337);

(b) the description of the Registrant’s common stock which is contained in a registration statement on [Form 8-A](#) filed on April 14, 2021 (File No. 001-40337) under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “**Exchange Act**”), including any amendment or report filed for the purpose of updating such description; and

(c) all other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8. Exhibits.**

The exhibits to this Registration Statement are listed below:

Exhibit Number	Description	Incorporated by Reference			Filing Date
		Schedule Form	File Number	Exhibit	
4.1	<a href="#">Amended and Restated Certificate of Incorporation of the Registrant.</a>	8-K	001-40337	3.1	April 26, 2021
4.2	<a href="#">Amended and Restated Bylaws of the Registrant.</a>	S-1/A	333-254663	3.4	April 14, 2021
4.3	<a href="#">Form of common stock certificate of the Registrant.</a>	S-1/A	333-254663	4.1	April 14, 2021
5.1*	<a href="#">Opinion of Cooley LLP.</a>				
23.1*	<a href="#">Consent of Cooley LLP (included in Exhibit 5.1).</a>				
23.2*	<a href="#">Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm.</a>				
24.1*	<a href="#">Power of Attorney (included on the signature page of this registration statement).</a>				
99.1	<a href="#">2021 Equity Incentive Plan.</a>	S-1/A	333-254663	10.6	April 14, 2021
99.2	<a href="#">Forms of Option Agreement, Stock Option Grant Notice and Notice of Exercise under the 2021 Equity Incentive Plan.</a>	S-1/A	333-254663	10.7	April 14, 2021
99.3	<a href="#">2021 Employee Stock Purchase Plan.</a>	S-1/A	333-254663	10.8	April 14, 2021
107*	<a href="#">Filing Fee Table</a>				

\* Filed herewith

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mountain View, State of California, on March 10, 2022.

### NeuroPace, Inc.

By: /s/ Michael Favet

Michael Favet  
President and Chief Executive Officer

## POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Favet, Rebecca Kuhn and Irina Ridley, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Michael Favet</u> Michael Favet	Director, President and Chief Executive Officer (Principal Executive Officer)	March 10, 2022
<u>/s/ Rebecca Kuhn</u> Rebecca Kuhn	Chief Financial Officer and Vice President, Finance and Administration (Principal Financial Officer and Principal Accounting Officer)	March 10, 2022
<u>/s/ Frank Fischer</u> Frank Fischer	Director	March 10, 2022
<u>/s/ Greg Garfield</u> Greg Garfield	Director	March 10, 2022
<u>/s/ Joseph S. Lacob</u> Joseph S. Lacob	Director	March 10, 2022
<u>/s/ Lisa Andrade</u> Lisa Andrade	Director	March 10, 2022
<u>/s/ Rakhi Kumar</u> Rakhi Kumar	Director	March 10, 2022
<u>/s/ Renee Ryan</u> Renee Ryan	Director	March 10, 2022



March 10, 2022

Mark B. Weeks  
T: +1 650 843 5011  
mweeks@cooley.com

NeuroPace, Inc.  
455 N. Bernardo Avenue  
Mountain View, CA 94043

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the filing by NeuroPace, Inc., a Delaware corporation (the "**Company**"), of a Registration Statement on Form S-8 (the "**Registration Statement**") with the Securities and Exchange Commission covering the offering of up to 1,467,178 shares (the "**Shares**") of the Company's Common Stock, \$0.001 par value, ("**Common Stock**") consisting of (a) 1,222,649 shares of Common Stock issuable pursuant to the Company's 2021 Equity Incentive Plan (the "**2021 EIP**") and (b) 244,529 shares of Common Stock issuable pursuant to the Company's 2021 Employee Stock Purchase Plan (together with the 2021 EIP, the "**Plans**").

In connection with this opinion, we have examined the Registration Statement and related prospectuses, the Plans, the Company's certificate of incorporation and bylaws, each as currently in effect, and such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed solely with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration Statement.

Very truly yours,

COOLEY LLP

By: /s/ Mark B. Weeks  
Mark B. Weeks

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the incorporation by reference in this Registration Statement on Form S-8 of NeuroPace, Inc. of our report dated March 10, 2022 relating to the financial statements, which appears in NeuroPace, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2021.

/s/ PricewaterhouseCoopers LLP

San Jose, California  
March 10, 2022

## CALCULATION OF FILING FEE TABLES

**Form S-8**  
(Form Type)**NeuroPace, Inc.**

(Exact Name of Registrant as Specified in its Charter)

Table 1 – Newly Registered Securities

	Security Type	Security Class Title	Fee Calculation Rule	Amount Registered <sup>(1)</sup>	Proposed Maximum Offering Price Per Unit	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Fees to be Paid	Equity	Common stock, \$0.001 par value per share, 2021 Equity Incentive Plan	Other <sup>(2)</sup>	1,222,649 <sup>(3)</sup>	\$ 7.55 <sup>(2)</sup>	\$ 9,230,999.95	.0000927	\$ 855.72
Fees to be Paid	Equity	Common stock, \$0.001 par value per share, 2021 Employee Stock Purchase Plan	Other <sup>(4)</sup>	244,529 <sup>(5)</sup>	\$ 6.42 <sup>(4)</sup>	\$ 1,569,876.18	.0000927	\$ 145.53
<b>Total Offering Amounts</b>					–	\$10,800,876.13	–	\$ 1,001.25
<b>Total Fees Previously Paid</b>					–	–	–	–
<b>Total Fee Offsets</b>					–	–	–	–
<b>Net Fee Due</b>					–	–	–	\$ 1,001.25

- (1) Pursuant to Rule 416(a) promulgated under the Securities Act of 1933, as amended, this Registration Statement shall also cover any additional shares of common stock of NeuroPace, Inc. (the “**Registrant**”) that become issuable under the Registrant’s 2021 Equity Incentive Plan (the “**2021 Plan**”) and the Registrant’s 2021 Employee Stock Purchase Plan (the “**2021 ESPP**”) by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected that results in an increase to the number of outstanding shares of Registrant’s common stock, as applicable.
- (2) Estimated in accordance with Rule 457(c) and (h) solely for the purpose of calculating the registration fee on the basis of \$7.55 per share of common stock, which represents the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Global Market on March 7, 2022.
- (3) Represents 1,222,649 additional shares of Registrant’s common stock that were automatically added to the shares authorized for issuance under the 2021 Plan on January 1, 2022 pursuant to an annual “evergreen” increase provision contained in the 2021 Plan. Pursuant to such provision, the number of shares reserved for issuance under the 2021 Plan will automatically increase on the first day of each calendar year, starting on January 1, 2022 and continuing through January 1, 2031, by the lesser of (a) 5% of the total number of shares of the Registrant’s common stock of all classes outstanding on December 31st of the immediately preceding calendar year and (b) a number of shares determined by the Registrant’s board of directors.
- (4) Estimated in accordance with Rule 457(c) and (h) solely for the purpose of calculating the registration fee on the basis of \$6.42 per share of common stock, which represents the average of the high and low prices of the Registrant’s common stock as reported on The Nasdaq Global Market on March 7, 2022, multiplied by 85%, which is the percentage of the price per share applicable to shares issued under the 2021 ESPP.
- (5) Represents 244,529 additional shares of common stock reserved for issuance under, and which annual increase is provided for in, the 2021 ESPP that were automatically added to the shares authorized for issuance under the 2021 ESPP on January 1, 2022 pursuant to an annual “evergreen” increase provision contained in the 2021 ESPP. Pursuant to such provision, the number of shares reserved for issuance under the 2021 ESPP will automatically increase on the first day of each calendar year, starting on January 1, 2022 and continuing through January 1, 2031, by the lesser of (a) 1% of the total number of shares of the Registrant’s common stock of all classes outstanding on December 31st of the immediately preceding calendar year, (b) 1,160,000 or (c) a number of shares determined by the Registrant’s board of directors.